My watch list  

PLIVA Acquires Uso Racional in Spain


PLIVA d.d. announced that an agreement has been signed with Novartis' generics division, Sandoz, for the purchase of its Spanish subsidiary Uso Racional S.L (UR) for a total cash consideration of EUR 21.5m. With expected sales of about EUR 12m in 2006, UR represents a well known and established generics brand in Spain, with a small dedicated sales force and a complementary product portfolio and attractive pipeline. The acquisition of UR represents a strong strategic fit with PLIVA's current Spanish operations, which PLIVA expects to help it significantly strengthen its position and performance on this market.

Facts, background information, dossiers
  • Pliva
  • generics
  • Spain
  • Sandoz
More about Sandoz
  • News

    Sandoz to invest $80 million in Boucherville facilities

    Sandoz Canada announced that it will invest $80 million in its Boucherville facilities as demand for its generic sterile injectable pharmaceuticals continues to grow in Canada and around the world. In addition to more than 100 new positions created in 2006, 100 additional jobs will be creat ... more

    Lek enhances its competitiveness with a new plant in Lendava

    Lek, a Sandoz company, opened a new plant at its Lendava site for the final phases of isolation of potassium clavulanate, which is the key ingredient of Amoksiklav, one of Lek's leading products that ranks among leading products also in Sandoz. Regular production of potassium clavulanate be ... more

More about PLIVA
  • News

    Right first time: Pioneering new methods of drug manufacture

    Engineers at the University of Leeds have developed a simple technology which can be used in existing chemical reactors to ensure "right first time" drug crystal formation. Ensuring drug crystals are formed correctly is crucial to their efficacy and the efficiency of pharmaceutical manufact ... more

    PLIVA to File Lawsuit Against HANFA

    PLIVA d.d. announced that it plans to file a lawsuit against the Croatian Financial Services Supervisory Agency (HANFA) with the Administrative Court of the Republic of Croatia, following the notification received on 22 January 2007 of HANFA's Ruling that PLIVA withheld price-sensitive info ... more

    PLIVA Announces Changes in Management and Supervisory Boards

    Barr Pharmaceuticals, Inc. and its newly acquired subsidiary PLIVA d.d. announced changes to the Management and Supervisory Boards of PLIVA d.d. The changes resulted from the meeting of PLIVA's Supervisory Board that was held on October 30, 2006 in Zagreb, Croatia. Following the successful ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE